---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-008819"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:30:22.341259+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents preliminary FY2022 revenue $34.7M; core product sales constant currency down 4.6%

## Summary
- Preliminary FY2022 total revenue $34.7M vs $43.2M in 2021; product sales $29.4M (Q4 $7.6M, +18% sequentially).
- Core non-COVID product sales $29.1M; constant currency ~$32.2M, down 4.6% from 2021.
- Q4 2022 core product sales constant currency $8.5M (+6% YoY); cumulative CytoSorb treatments >195,000 (+20% YoY).
- Cash $23.8M at year end; $5M Bridge Bank term loan in Dec; expects product gross margins 75-80% in 2023.
- STAR-T trial for DrugSorb-ATR: 1/3 of 120 patients enrolled; DSMB cleared; completion expected summer 2023; FDA submission planned.

## SEC filing metadata
- accession: 0001104659-23-008819
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/0001104659-23-008819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/tm234948d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-008819
- JSON: https://secwatch.observer/filing/0001104659-23-008819.json
- Plain text: https://secwatch.observer/filing/0001104659-23-008819.txt

## Key facts
- Earnings Releases
  Cytosorbents Corp reported preliminary unaudited full year 2022 results: revenue approximately $34.7 million.
  - Period: preliminary unaudited full year 2022
  - Revenue: approximately $34.7 million
  - Result: preliminary results
  source text: Preliminary unaudited 2022 Total Revenue, which includes Product Sales and Grant Revenue, was approximately $34.7 million versus $43.2 million in 2021, and $24.9 million in pre-pandemic 2019
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/0001104659-23-008819-index.htm
- Earnings Releases
  Cytosorbents Corp reported preliminary unaudited fourth quarter 2022 results: revenue approximately $9.4 million.
  - Period: preliminary unaudited fourth quarter 2022
  - Revenue: approximately $9.4 million
  - Result: preliminary results
  source text: Q4 2022 Total Revenue was approximately $9.4 million versus $10.8 million in Q4 2021, and versus $7.4 million in pre-pandemic Q4 2019
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465923008819/0001104659-23-008819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.